ArticleCancer biomarkers : section A of Disease markers2016
Serum TK1 is a more reliable marker than CEA and AFP for cancer screening in a study of 56,286 people.
Article in Cancer biomarkers : section A of Disease markers, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 47 citations in OpenAlex.
- A Novel Model Using Serum Thymidine Kinase 1 and Low-dose Computed Tomography Parameters to Predict Three-year Lung Cancer Risk in People with Pulmonary Nodules: A Retrospective Study.Journal of Cancer · 2024Article
- Thymidine kinase 1 appears to be a marker for the prognosis of hepatocellular carcinoma based on a large-scale, multicenter study.Journal of cancer research and clinical oncology · 2023Article
- The role of heavy metals in the development of colorectal cancer.BMC cancer · 2023Article
- Integrated Bioinformatics Investigation of Novel Biomarkers of Uterine Leiomyosarcoma Diagnosis and Outcome.Journal of personalized medicine · 2023Article
- Is serum thymidine kinase 1 a prognostic biomarker in primary tumor location of colorectal carcinomas?Discover oncology · 2023Article
- Multi-Omics Integration Analysis of TK1 in Glioma: A Potential Biomarker for Predictive, Preventive, and Personalized Medical Approaches.Brain sciences · 2023Article
- Regulatory T cells are associated with the tumor immune microenvironment and immunotherapy response in triple-negative breast cancer.Frontiers in immunology · 2023Article
- Thymidine Kinase 1 Drives Skin Cutaneous Melanoma Malignant Progression and Metabolic Reprogramming.Frontiers in oncology · 2022Article
- Serum thymidine kinase 1 protein concentration for predicting early progression and monitoring the response to TACE in hepatocellular carcinomas: a network meta-analysis.Future science OA · 2021Article
- Economical and easily detectable markers of digestive tumors: platelet parameters.Biomarkers in medicine · 2021Article
- Thymidine kinase 1 through the ages: a comprehensive review.Cell & bioscience · 2020Review
- STK1p as a prognostic biomarker for overall survival in non-small-cell lung carcinoma, based on real-world data.Future science OA · 2020Article
- A meta-analysis of serological thymidine kinase 1 as a marker for colorectal benign and malignant tumor risk assessment.Molecular and clinical oncology · 2020Article
- Correlation study between serum neuro-specific enolase and gastric and colorectal cancers.Medicine · 2020Observational
- Observational
- Novel monoclonal antibodies against thymidine kinase 1 and their potential use for the immunotargeting of lung, breast and colon cancer cells.Cancer cell international · 2020Article
- Hadrontherapy Interactions in Molecular and Cellular Biology.International journal of molecular sciences · 2019Review
- Loss of thymidine kinase 1 inhibits lung cancer growth and metastatic attributes by reducing GDF15 expression.PLoS genetics · 2019Article
- MicroRNAs as biomarkers for the progression and prognosis of colon carcinoma.International journal of molecular medicine · 2018Article
- Membrane expression of thymidine kinase 1 and potential clinical relevance in lung, breast, and colorectal malignancies.Cancer cell international · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe World Health Organization (WHO) has estimated that the number of cancer patients will increase by about 70% during the next 25 years world-wide. To deal with this problem, WHO has suggested a focus on prevention of tumor incidence and health screening for early detection of people with tumors.
objectiveTo investigate the use of thymidine kinase 1 (TK1), CEA and AFP in serum to discover people with malignant tumors through health cancer screening.
methodsOf a cohort in 486,085 people of a routine health screening at the Health Centre, Fujun 180 Hospital, Quanzhou city, China, 56,286 people were investigated according to the presence of cancer during 2009-2014. The concentration of CEA and AFP were determined by an electrochemiluminescence immunoassay from Roche Diagnostics e601GmbH and STK1 by a commercial kit based on an enhanced chemiluminescent dot blot assay.
resultsThe cancer incident rate increased from 0.048/100,000 to 0.220/100,000. The most common types of tumors were those of the liver, cervix and lung. STK1 correlated to tumor growth rate, was more sensitive than CEA and AFP for discovering people with malignant tumors and more sensitive among people who had diagnosis of malignant tumor. STK1 was also a prognostic biomarker for death at 10-40 months follow-up, while CEA and AFP were not. A combination of these markers increased the sensitivity by about 30%.
conclusionSTK1 is a reliable biomarker for discovering people with malignant tumors in cancer screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.